Ardea Biosciences Presents Additional Phase 2a And Preclinical Data On Its Lead HIV Product Candidate, RDEA806

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that additional data from a Phase 2a monotherapy study of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of human immunodeficiency virus (HIV), were presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC. Dr.

More: continued here

Filed under: Clinical Trials on October 28th, 2008